Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2017

01-10-2017 | Original article

Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience

Authors: Takeshi Ninchoji, Kandai Nozu, Keita Nakanishi, Tomoko Horinouchi, Junya Fujimura, Tomohiko Yamamura, Shogo Minamikawa, Shingo Ishimori, Koichi Nakanishi, Norishige Yoshikawa, Ichiro Morioka, Hiroshi Kaito, Kazumoto Iijima

Published in: Clinical and Experimental Nephrology | Issue 5/2017

Login to get access

Abstract

Objectives

To clarify the clinical characteristics and long-term outcomes of patients with diarrhea-associated hemolytic uremic syndrome (D + HUS) with a particular focus on time course.

Methods

We retrospectively analyzed the medical records of 61 patients with D + HUS who were admitted to Kobe University Hospital between 1995 and 2015. The onset of D + HUS was defined as day 1 of diarrhea.

Results

The age of onset was 4.1 (1.5–13.4) years, and the period between onset and diagnosis of D + HUS was 5 (3–18) days. The platelet count was lowest on day 7 (4–24), and the lactase dehydrogenase level was maximal on day 8 (4–25). Twenty-three patients required dialysis for 13 (2–37) days, starting at day 5–9. Seventeen patients showed central nervous system (CNS) symptoms at day 4–18. They were followed up for 3.7 (0–18.4) years. At the final follow-up, estimated glomerular filtration rate was 113.7 (57.9–159.9) ml/min/1.73 m2 with five patients having chronic kidney disease. Three patients developed CNS sequelae. The time to diagnosis was significantly shorter in the group of patients receiving dialysis than without dialysis (p = 0.018) and in the group with CNS complications than without (p = 0.013).

Conclusion

CNS complications were often apparent after blood examination results improved. Moreover, a shorter period between the onset of diarrhea and a diagnosis of D + HUS indicated a more severe clinical course or long-term sequelae, and it should be considered as a risk factor for poor prognosis.
Literature
1.
go back to reference Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol. 2013;28:2097–105.CrossRefPubMed Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol. 2013;28:2097–105.CrossRefPubMed
2.
go back to reference Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome. JAMA. 2003;290:1360–70.CrossRefPubMed Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome. JAMA. 2003;290:1360–70.CrossRefPubMed
3.
go back to reference Sheth KJ, Swick HM, Naworth N. Neurological involvement in hemolytic-uremic syndrome. Ann Neurol. 1986;19:90–3.CrossRefPubMed Sheth KJ, Swick HM, Naworth N. Neurological involvement in hemolytic-uremic syndrome. Ann Neurol. 1986;19:90–3.CrossRefPubMed
4.
go back to reference Sylvie N, Theresa K, Monique E, Marina C, Emma AL, Jerome H, Muriel B, Bruno R, Flavio B, Sylvie C, Guylhene BM, Christine P, Gerard C, Tim U, George D. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–28.CrossRef Sylvie N, Theresa K, Monique E, Marina C, Emma AL, Jerome H, Muriel B, Bruno R, Flavio B, Sylvie C, Guylhene BM, Christine P, Gerard C, Tim U, George D. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–28.CrossRef
5.
go back to reference Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics. 2006;117:1656–62.CrossRefPubMed Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics. 2006;117:1656–62.CrossRefPubMed
6.
go back to reference Yamamoto T, Datomura K, Okada S, Ozono K. Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157. Pediatr Int. 2009;51:216–9.CrossRefPubMed Yamamoto T, Datomura K, Okada S, Ozono K. Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157. Pediatr Int. 2009;51:216–9.CrossRefPubMed
7.
go back to reference Kamioka I I, Yoshiya K, Satomura K, Kaito H, Fujita T, Iijima K, Nakanishi K, Yoshikawa N, Nozu K, Matsuo M. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int. 2008;50:441–6.CrossRefPubMed Kamioka I I, Yoshiya K, Satomura K, Kaito H, Fujita T, Iijima K, Nakanishi K, Yoshikawa N, Nozu K, Matsuo M. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int. 2008;50:441–6.CrossRefPubMed
8.
go back to reference Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999 to 2008. BMC Infect Dis. 2016;16:285.CrossRefPubMedPubMedCentral Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999 to 2008. BMC Infect Dis. 2016;16:285.CrossRefPubMedPubMedCentral
9.
go back to reference Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O157-induced hemolytic uremic syndrome: usefulness of SCWP score for the prediction of neurological complication. Pediatr Int. 2009;51:107–9.CrossRefPubMed Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O157-induced hemolytic uremic syndrome: usefulness of SCWP score for the prediction of neurological complication. Pediatr Int. 2009;51:107–9.CrossRefPubMed
10.
go back to reference Buder K, Latal B, Nef S, Neuhaus TJ, Laube GF, Spartà G. Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome. Pediatr Nephrol. 2015;30:503–13.CrossRefPubMed Buder K, Latal B, Nef S, Neuhaus TJ, Laube GF, Spartà G. Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome. Pediatr Nephrol. 2015;30:503–13.CrossRefPubMed
11.
go back to reference Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K, Kitagawa T. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol. 2011;15:694–9.CrossRefPubMed Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K, Kitagawa T. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol. 2011;15:694–9.CrossRefPubMed
12.
go back to reference Hoste L, Dubourg L, Selistre L, De Souza VC, Ranchin B, Hadj-Aïssa A, Cochat P, Martens F, Pottel H. A new equation to estimate the glomerular filtration rate in children, adolescents and young adults. Nephrol Dial Transpl. 2014;29(5):1082–91.CrossRef Hoste L, Dubourg L, Selistre L, De Souza VC, Ranchin B, Hadj-Aïssa A, Cochat P, Martens F, Pottel H. A new equation to estimate the glomerular filtration rate in children, adolescents and young adults. Nephrol Dial Transpl. 2014;29(5):1082–91.CrossRef
13.
go back to reference Takanashi J, Taneichi H, Misaki T, Yahata Y, Okumura A, Ishida Y, Miyawaki T, Okabe N, Sata T, Mizuguchi M. Clinical and radiologic features of encephalopathy during 2011 E. coli O111 outbreak in Japan. Neurology. 2014;82:564–72.CrossRefPubMed Takanashi J, Taneichi H, Misaki T, Yahata Y, Okumura A, Ishida Y, Miyawaki T, Okabe N, Sata T, Mizuguchi M. Clinical and radiologic features of encephalopathy during 2011 E. coli O111 outbreak in Japan. Neurology. 2014;82:564–72.CrossRefPubMed
14.
go back to reference Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Shwartz J, Weinstein R, Shaz BH. Apheresis Applications Committee of the American Society for Apheresis. Guideline on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83–177.CrossRefPubMed Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Shwartz J, Weinstein R, Shaz BH. Apheresis Applications Committee of the American Society for Apheresis. Guideline on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83–177.CrossRefPubMed
15.
go back to reference Colic E, Hans D, Kjell T, Martin T. Management of an acute outbreak of diarrhea-associated haemolytic uremic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011;378:1089–93.CrossRefPubMed Colic E, Hans D, Kjell T, Martin T. Management of an acute outbreak of diarrhea-associated haemolytic uremic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011;378:1089–93.CrossRefPubMed
16.
go back to reference Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, WTA Todd. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157: H7 outbreak. Lancet. 1999;354:1327–30.CrossRefPubMed Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, WTA Todd. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157: H7 outbreak. Lancet. 1999;354:1327–30.CrossRefPubMed
17.
go back to reference Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23:1749–60.CrossRefPubMed Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23:1749–60.CrossRefPubMed
18.
go back to reference Shimizu M, Kuroda M, Inoue N, Konishi M, Igarashi N, Taneichi H, Kanegane H, Ito M, Saito S, Yachie A. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014;66:1–6.CrossRefPubMed Shimizu M, Kuroda M, Inoue N, Konishi M, Igarashi N, Taneichi H, Kanegane H, Ito M, Saito S, Yachie A. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014;66:1–6.CrossRefPubMed
19.
go back to reference Michael M, Elliot EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenia purpura: a systemic review of randomized controlled trials. Am J Kidney Dis. 2009;53:259–72.CrossRefPubMed Michael M, Elliot EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenia purpura: a systemic review of randomized controlled trials. Am J Kidney Dis. 2009;53:259–72.CrossRefPubMed
Metadata
Title
Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience
Authors
Takeshi Ninchoji
Kandai Nozu
Keita Nakanishi
Tomoko Horinouchi
Junya Fujimura
Tomohiko Yamamura
Shogo Minamikawa
Shingo Ishimori
Koichi Nakanishi
Norishige Yoshikawa
Ichiro Morioka
Hiroshi Kaito
Kazumoto Iijima
Publication date
01-10-2017
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-016-1376-3

Other articles of this Issue 5/2017

Clinical and Experimental Nephrology 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine